Following its notice of interim results, shares in Deltex Medical Group (DEMG) rose by 27% (0.325 per share) yesterday afternoon in anticipation of the results, which will be announced next Monday 24th September.
Deltex is the global leader in its proprietary Oesophageal Doppler Monitoring (ODM) - the only technology to measure blood flow in central circulation in real time.
It is also the only group in the enhanced haemodynamic space, having built a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVue Doppler, which has been demonstrated to reduce complications suffered by patients after surgery.
The group aims to provide clinicians with a single platform - called a "haemodynamic workstation" - that offers them a range of technologies.
This will enable the company to partner with healthcare providers to support modern haemodynamic management across the whole hospital.
Houser broker ED and Arden Partners have set target prices ranging between 8.72p and 10.2p.
Deltex Medical is currently in the implementing phase in the UK, USA, Canada and Spain, with distribution arrangements in place in a further 30 countries.
The group has seen a number of new accounts coming onboard in the US market, including a very major account after a rigorous and successful evaluation.
According to a statement by Chairman Nigel Keen, the group has made progress towards profitability and reduced overheads, having “put the Group on a significantly more secure financial footing” after raising £2.0m in additional capital and reducing cash costs by £1.0m.
After a wave of 2018 M&A activity in the biotech space, there is speculation the company could be a potential target - not surprising given its proprietary technology and new promising accounts lined up.
Follow news & updates about Deltex Medical Group here:
Trading volume in Asiamet shares are 600% above the monthly average, as investors look to take advantage of the recent dip in price the company experienced following the speculation regarding protests in the Nagan Raya area where its Beutong asset is located.
Philip Hammond gets a £10 billion boost for Budget spending after fall in borrowing, China growth slowest since financial crisis as trade war looms.
Andalas Energy (ADL), recently released its corporate presentation to the public underlining its new ongoing strategy. The oil and gas exploration and production company explores opportunities in assets in the UK and Indonesia.
Read a roundup of This Week’s Trading Updates: Broker and Tipster Sentiment by Stockomendation Analyst James Bowden.
On today's podcast: David Ciclitira, Executive Chairman of Live Company Group (LVCG) talks about their recent acquisition of Bright Bricks and about general progress at the company. Also Russ Mould, Investment Director at stockbroker AJ Bell talks about: Zytronic (ZYT), Redcentric (RCN) & Tharisa (THS).
SP Angel morning note on commodities featuring: Scotgold Resources* (SGZ LN) – Cononish update
See Today's AIM Risers Featuring Safestay, CAP-XX, Fontera Resources and PhotonStar LED Group
Unilever overhaul could be ditched after backlash, Amazon creates 1,000 new UK research roles as tech giants hone in on British talent, HSBC to list shares in Shanghai in ‘symbolic’ move
Five financial stories, trending today in a 70 second podcast, including: Food sales saw their steepest drop in three years in September as consumers tightened their belts after the unusually hot summer, the Office for National Statistics (ONS) has said. Sales of food were down 1.5% in the month, contributing to a 0.8% fall in total UK retail sales.
As predicted, shares in New York have fallen into the red in early trading, Unilever has ‘no regrets’ on U-turn over HQ as sales grow